-
Subject Areas on Research
-
2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
-
A fully automated artificial intelligence method for non-invasive, imaging-based identification of genetic alterations in glioblastomas.
-
A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation.
-
A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation.
-
A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation.
-
A pyruvate cycling pathway involving cytosolic NADP-dependent isocitrate dehydrogenase regulates glucose-stimulated insulin secretion.
-
Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities.
-
Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.
-
An SOD mimic protects NADP+-dependent isocitrate dehydrogenase against oxidative inactivation.
-
An integrated genomic analysis of human glioblastoma multiforme.
-
Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.
-
Biological Role and Therapeutic Potential of IDH Mutations in Cancer.
-
Breaking Cryo-EM Resolution Barriers to Facilitate Drug Discovery.
-
CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas.
-
CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP.
-
Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia.
-
Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability.
-
Centronuclear myopathy: histochemistry and electron microscopy. Report of two cases.
-
Control of voltage-gated potassium channel Kv2.2 expression by pyruvate-isocitrate cycling regulates glucose-stimulated insulin secretion.
-
Culture kinetics of glycolytic enzyme induction, glucose utilization, and thymidine incorporation of extended-exposure phytohemagglutinin-stimulated human lymphocytes.
-
Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq.
-
Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.
-
Distinct Roles of Glutamine Metabolism in Benign and Malignant Cartilage Tumors With IDH Mutations.
-
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
-
Enzyme redesign guided by cancer-derived IDH1 mutations.
-
Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers.
-
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.
-
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
-
Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila.
-
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.
-
Glioma progression is shaped by genetic evolution and microenvironment interactions.
-
Heterogeneity of tumor-induced gene expression changes in the human metabolic network.
-
Hitting Gliomas When They Are Down: Exploiting IDH-Mutant Metabolic Vulnerabilities.
-
IDH1 and IDH2 hotspot mutations are not found in canine glioma.
-
IDH1 and IDH2 mutations in gliomas.
-
IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain.
-
IDH3α regulates one-carbon metabolism in glioblastoma.
-
Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.
-
Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy.
-
Improved grading of IDH-mutated astrocytic gliomas.
-
Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology.
-
Intracellular cholesterol biosynthesis in enchondroma and chondrosarcoma.
-
Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.
-
Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.
-
Isocitrate dehydrogenase is important for nitrosative stress resistance in Cryptococcus neoformans, but oxidative stress resistance is not dependent on glucose-6-phosphate dehydrogenase.
-
Isocitrate dehydrogenase mutations in gliomas.
-
Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target.
-
Isocitrate-to-SENP1 signaling amplifies insulin secretion and rescues dysfunctional β cells.
-
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
-
Longitudinal molecular trajectories of diffuse glioma in adults.
-
Management of glioblastoma: State of the art and future directions.
-
Mitochondrial acetylome analysis in a mouse model of alcohol-induced liver injury utilizing SIRT3 knockout mice.
-
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.
-
Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States.
-
Molecular profiling of different glioma specimens from an Ollier disease patient suggests a multifocal disease process in the setting of IDH mosaicism.
-
Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas.
-
Mutant IDH is sufficient to initiate enchondromatosis in mice.
-
Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression.
-
Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process.
-
Mutant IDH1 is required for IDH1 mutated tumor cell growth.
-
Mutant metabolic enzymes are at the origin of gliomas.
-
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.
-
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
-
National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.
-
Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.
-
Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come.
-
Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation.
-
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.
-
Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
-
Radiogenomics of lower-grade glioma: algorithmically-assessed tumor shape is associated with tumor genomic subtypes and patient outcomes in a multi-institutional study with The Cancer Genome Atlas data.
-
Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.
-
Radioprotection of lipogenesis from glucose (U-14C) and activities of pyridine nucleotide dehydrogenases in liver of gamma-irradiated female rats by cystamine.
-
Reductive TCA cycle metabolism fuels glutamine- and glucose-stimulated insulin secretion.
-
Reflecting on survivorship outcomes to aid initial decision making in patients treated for IDH-mutated anaplastic glioma.
-
Releasing the block: setting differentiation free with mutant IDH inhibitors.
-
Role of Ethnicity and Geographic Location on Glioblastoma IDH1/IDH2 Mutations.
-
Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas.
-
Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma.
-
Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors.
-
Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies.
-
The Cancer Genome Atlas expression profiles of low-grade gliomas.
-
The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.
-
The implications of IDH mutations for cancer development and therapy.
-
The preparation of stereospecific tritium-labeled reduced nicotinamide adenine dinucleotide phosphate.
-
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.
-
Understanding the Genetic Risk of IDH-Mutant Glioma.
-
Vitamin A and biochemical development. II. Effect of postnatal excess vitamin-A administration on the activity of pyridine nucleotide-linked dehydrogenases.
-
Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment.
-
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.
-
Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy.
-
Keywords of People